Get 50% OFF This Summer!
ERIS Lifesciences
No Data Available
Investor Sentiment
ERIS Lifesciences Share price and Fundamental Analysis
Key Metrics
Included In
Stock Returns
CAGR
Revenue Growth
Net Profit Growth
Operating Profit Growth
Dividend Growth
Stock Returns CAGR
Stock Heatmap
No Stocks
Smart Score
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
Technicals
Returns Calculator
If you would have investedResearch Report
No Research Report
Corporate Action
Financials
Key Ratios
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
Dividend History
5 Year FactSheet
Documents
No Data Available
News
ERIS Lifesciences Management and History
Company Management
Unlock Management Data
See Detailed Analysis & Insights
Company History
Eris Lifesciences Limited was incorporated on January 25, 2007. Subsequently, the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9, 2007. Further, the Company was converted into a Public Limited cCompany and the name was changed to 'Eris Lifesciences Limited' on February 2, 2017. The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products. It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors. Apart from this, it has a portfolio of 112 Mother Brands across therapy areas.
The company develops, manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market (IPM), such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infective. Its focus has been on developing products in the chronic and acute categories which are linked to lifestyle related disorders. Its operations are supported by a distribution network of 22 Sales depots, 2,059 Stockists and more than 5,00,000 retail chemists.
In 2007, the company launched 'Eris' division focused on cardiology and diabetes segment. In 2008, the company launched 'Nikkos' division focused on gastroenterology and orthopedics segment. In 2009, the company launched 'Adura' division focused on cardiology and diabetes segment. In 2011, the company launched 'Montana' division focused on gynecology and pediatrics segment. In 2012, the company launched 'Inspira' division focused on cardiology segment.
In 2014, the company launched 'Victus' division focused on anti-diabetes segment. During the year, the company set up manufacturing facility at Assam. In 2015, the company launched 'Eris 2' division focused on pain management segment.
In 2016, the company acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now, Aprica Pharmaceuticals Private Limited). During the year, the company acquired 100% of the outstanding equity shares of Aprica Healthcare Private Limited and 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited.
In 2017, the company acquired the trademarks UNION', REUNION' and BON UNION'.
Eris Lifesciences made its debut on the secondary equity market on 29 June 2017. The stock debuted at Rs 612 on BSE compared with the initial public offer (IPO) price of Rs 603.
In October 2017, Eris Lifesciences Ltd (Eris) acquired the entire shareholding of UTH Healthcare Ltd (UTH) for an all-cash consideration of Rs 129 million. UTH is largely engaged in the segments of obesity, diabetes, gestational diabetes mellitus, maternal nutrition, and cardio-vascular diseases. The acquisition provides Eris with a portfolio of products that complement its other offerings.
In December 2017, Eris Lifesciences Ltd (Eris) acquired the Indian branded formulations business of Strides Shasun Ltd (Strides) for an aggregate cash consideration of Rs 5000 crore. With this acquisition, Eris acquired the marketing and distribution rights for India for 130+ brands in the Neurology, Psychiatry, Nutraceuticals and Women Healthcare therapy areas. The Indian branded formulations business being divested by Strides had sales of Rs 181 crore for FY 2017.
During the year 2018, capital expenditure amounted to Rs 242.69 million. Additionally, consideration of Rs. 5,061.52 million was paid towards business acquisition.
During the year 2018, UTH Healthcare Limited and Eris Healthcare Private Limited (earlier known as Strides Healthcare Private Limited) became subsidiaries of the Company.
As on March 31, 2019, the Company has 5 subsidiaries out of which 4 are wholly owned subsidiaries.
During the year 2019, capital expenditure amounted to Rs 374.15 million. Additionally, consideration of Rs. 107.22 million was paid towards business acquisition.
In April 2019, the Company acquired the remaining shares of Kinedex Healthcare Private Limited, thereby making it a wholly owned subsidiary. It launched new business divisions, ErisART, Nutriverse, Aspire, Oncosciences, Filix, and Allure. A newly constructed facility for soft-gel was added in the year 2019 with total production capacity of 75 mn units. An extended facility has been included for supplements and Nutraceuticals with an additional capacity of 60 mn tablets, 41 mn capsules and 4 mn sachets. In December 2019, it launched Zomelis, after acquiring the trademark from Novartis.
As on March 31, 2020, the Company has 5 five wholly owned subsidiaries. During the year 2020, the Company has acquired the remaining shares of Kinedex Healthcare Private Limited, thereby making it a wholly owned subsidiary. Eris Healthcare Private Limited has incorporated subsidiary company 'Eris Pharmaceuticals Private Limited' on 2nd, June 2020. In Q3 FY 20, the Company launched Rariset, under their in-licensing agreement with Pharmanutra S.P.A for their patent protected Sucrosomial Iron.
As on March 31, 2021, the Company has 3 three wholly owned and 1 other than wholly owned subsidiaries. During the year 2021, two Companies namely Aprica Healthcare Limited and Eris Therapeutics Private Limited ceased to be subsidiaries of the Company. Eris Healthcare Private Limited, wholly owned subsidiary of the Company, had incorporated a subsidiary company 'Eris Pharmaceuticals Private Limited' on 2nd June, 2020.
In FY'21. the Company strengthened portfolio with Gluxit, its Dapagliozin brand in the strategically important SGLT 2 segment launched in October'20. Eritel and LNBloc maintained ranks in their respective segments and made a debut in fast-growing anti-thrombotics segment through the launch of Rivalto, Rivaroxaban offering. It fortified portfolio with the launch of ZACD, an immunity-enhancing formulation and added Bricet to its portfolio. Of the top 4 Mother Brands - Serlift, Desval ER, Sonaxa and Levroxa while Serlift, and Desval ER maintained theirranks in their respective segments.
As on March 31, 2022, the Company has 3 wholly-owned subsidiaries and 2 other than wholly owned subsidiaries. In 2022, Eris Therapeutics Limited, wholly owned subsidiary of the Company, was incorporated on 23rd June, 2021. The Company's wholly owned subsidiary Eris M.J. Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited) issued fresh shares through private placement, pursuant to which Eris holding had 70% in Eris M.J. Biopharm Private Limited. It launched human insulin through subsidiary, Eris MJ Biopharm Ltd. In Q4 FY 22, it launched Xsulin in the forms of vials and cartridges.
During the year 2023, the Company acquired 100% stake in Eris Oaknet Healthcare Private Limited in 2023. It launched Glura, a DPP4 Inhibitor. In Jan'23, it acquired 9 Derma brands from Glenmark for Rs 3,400 million and in Mar'23, it acquired 9 Cosmetology brands from Dr Reddy's for Rs 2,750 million.
In 2022-23, Eris Healthcare Private Limited, a wholly owned subsidiary, demerged its Acquired Brands business to the Aprica Healthcare Limited, a wholly owned subsidiary, through a Scheme of Arrangement effective December 23, 2022.
ERIS Lifesciences Share Price
ERIS Lifesciences share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
ERIS Lifesciences Market Cap
Market capitalization of ERIS Lifesciences indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how ERIS Lifesciences is valued compared to its competitors.
ERIS Lifesciences PE Ratio
ERIS Lifesciences PE ratio helps investors understand what is the market value of each stock compared to ERIS Lifesciences 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
ERIS Lifesciences PEG Ratio
The PEG ratio of ERIS Lifesciences evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
ERIS Lifesciences ROE (Return on Equity)
Return on Equity (ROE) measures how effectively ERIS Lifesciences generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
ERIS Lifesciences ROCE (Return on Capital Employed)
Return on Capital Employed (ROCE) evaluates the profitability of ERIS Lifesciences in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
ERIS Lifesciences Total Debt
Total debt of ERIS Lifesciences shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
ERIS Lifesciences Debt to Equity Ratio
The Debt-to-Equity (DE) ratio of ERIS Lifesciences compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
ERIS Lifesciences CAGR (Compound Annual Growth Rate)
CAGR shows the consistent growth rate of ERIS Lifesciences over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
ERIS Lifesciences Technical Analysis
Technical analysis of ERIS Lifesciences helps investors get an insight into when they can enter or exit the stock. Key components of ERIS Lifesciences Technical Analysis include:
Support Levels (S1, S2, S3)
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
Resistance Levels (R1, R2, R3)
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where ERIS Lifesciences shares often struggle to rise above due to selling pressure.
ERIS Lifesciences Dividends
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect ERIS Lifesciences ’s financial health and profitability.
ERIS Lifesciences Bonus Shares
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
ERIS Lifesciences Stock Split
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
ERIS Lifesciences Financials
The financials of ERIS Lifesciences provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
ERIS Lifesciences Profit and Loss Statements
The profit and loss statement of ERIS Lifesciences highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of ERIS Lifesciences .
ERIS Lifesciences Balance Sheet
The balance sheet presents a snapshot of ERIS Lifesciences ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
ERIS Lifesciences Cashflow Statements
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
Download the App
SEBI REGISTERED RESEARCH ANALYST REGISTRATION NUMBER: INH000015729Disclaimer: "Investments in securities are subject to market risks. Read all the related documents carefully before investing." Receiving registration from SEBI and certification from NISM does not assure the performance of the intermediary or guarantee returns to investors in any manner. Compliance Email: [email protected]
Features
Portfolio Analysis
Screener
Stock compare
Buckets
Watchlist
Superstar Portfolio
Market
List of BSE200 Companies
List of NIFTY500 Companies
List of NIFTY NEXT 50 Companies
NIFTY Top gainers in 5 Days
NIFTY100 Most Active Stocks
NIFTY Top Gainers in 1 Month